A new study being conducted by QualityMetric, which specializes in patient-reported outcomes research, is seeking to understand why patients in Canada who get the Shingrix vaccine do or do not get both doses.
The study will include input from patients, age 50 and older, who received the vaccine between January 2018 and March 2020. Shingrix is a 2-dose vaccine; the second dose should be administered 2-6 months after the first dose.
At this time, participants are needed who are age 50+ and meeting 1 of the following criteria:
- Adults who received only 1-dose of Shingrix (i.e., they did not finish the series)
- Adults who received both doses of Shingrix, but the second one was administered less than 2 months OR more than 6 months after the first
Qualified participants will conduct a 60-minute interview, and be required to show proof of vaccination record(s). They will receive a 255$ CAD honorarium.
QualityMetric’s partners at QualWorld are helping to manage the screening and scheduling for interested individuals. Interested individuals can contact [email protected] for more information and/or to determine if they are eligible to participate in the study.
This study is sponsored by GlaxoSmithKline (GSK).